Natera Inc (NTRA)

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory MelanomaMay 29, 2026 6:00 AM
Business Wire Signatera™ to evaluate molecular response to investigational dendritic cell therapy as part of Diakonos’ Phase I/II trial Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the collaboration, Signatera will be used to longitudinally assess molecular response in patients with refractory melanoma enrolled in Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial. The DOC-RM trial, which began enrollment in May, is evaluating DOC1021 (dubodencel), a first-in-class, personalized dendritic cell investigational therapy that recently received Fast Track designation by the U.S. Food and Drug Administration (FDA) in unresectable or metastatic cutaneous melanoma. With Signatera, Natera will conduct analyses of circulating tumor DNA (ctDNA) at multiple timepoints during and following treatment. Refractory melanoma is an area of significant unmet need. Although immunotherapy has transformed the treatment landscape for advanced melanoma, many patients either do not respond or eventually develop resistance, underscoring the need for novel therapeutic approaches. Because radiographic response assessment can be challenging in immunotherapy-treated patients, serial ctDNA monitoring may provide earlier insight into molecular response and disease dynamics during treatment.1 "With an FDA Fast Track designation in hand, DOC1021’s path forward in refractory melanoma will benefit from early, high-quality evidence of activity,” said Jay Hartenbach, president and COO of Diakonos Oncology. “Natera’s Signatera test is the most trusted tumor-informed MRD platform in oncology, making them a natural partner to help evaluate molecular response in a population where imaging often lags the biology.” “Signatera is uniquely positioned to help biopharma partners evaluate molecular response throughout the course of therapy, and we are thrilled to partner with Diakonos on this exciting program,” said Eric Matthews, general manager, BioPharma, Natera. “By assessing MRD status across multiple timepoints, this collaboration has the potential to provide deep insight into treatment response dynamics and support future development efforts for patients with difficult-to-treat cancers.” Resources Ribas A, et al. Search for effective treatments in patients with advanced refractory melanoma. Journal for ImmunoTherapy of Cancer. 2021;9:e002820. doi:10.1136/jitc-2021-002820. About Natera Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our or our partners’ efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov. View source version on businesswire.com: https://www.businesswire.com/news/home/20260529102657/en/ Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com Original: Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing TechnologyMay 26, 2026 6:00 AM
Business Wire Study provides prospective, clinically-validated performance data at challenging low fetal fraction levels, raising industry standard Reduces no-call rate to 0.5%, enabling results for more patients and closing a key competitive gap Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive prenatal test (NIPT). Powered by the company’s novel SNP-informed deep sequencing technology, Panorama NIPT is now backed by clinically-validated performance data in samples with low fetal fraction, enabling a no-call rate of 0.5%. Fetal fraction refers to the proportion of placental DNA circulating in a pregnant patient’s blood sample. Low fetal fraction can make it more difficult to accurately detect chromosomal abnormalities in prenatal screening. Patients with low fetal fraction are associated with a significantly increased risk of aneuploidy. Prior literature highlights challenges with sensitivity at low fetal fractions with some counting-based NIPT methods, with one study indicating 62% sensitivity for trisomy 21 at low fetal fraction.1,2 Despite this limitation, most counting-based NIPTs routinely provide results at low fetal fraction without providing clinical performance data specifically for these populations. To address this unmet need, Natera developed and validated SNP-informed deep sequencing technology to improve NIPT performance at low fetal fractions while preserving the unique advantages of Panorama’s SNP-based methodology. Panorama with SNP-informed deep sequencing technology is supported by a prospective, blinded clinical validation study of 3,323 high- and low-risk pregnant patients, including 242 samples with low fetal fraction or that would not have received a result otherwise. All samples had outcomes confirmed by diagnostic genetic testing. While most counting-based NIPT studies report blended performance across fetal fractions, thereby obscuring performance at low fetal fractions, results from this study demonstrated strong clinical performance explicitly in patients at low levels of fetal fraction, including 100% sensitivity for trisomy 21, 93.3% sensitivity for trisomy 18, and 100% sensitivity for trisomy 13. In addition, the no-call rate was reduced to just 0.5%, enabling more patients to receive actionable results on the first draw and removing a historical competitive gap for Panorama. “Low fetal fraction has remained one of the most important challenges in non-invasive prenatal screening,” said Sheetal Parmar, M.S., CGC, SVP of Medical Affairs, Women’s Health. “Panorama now combines the power of our proprietary SNP-based approach with a novel deep sequencing technology that maintains strong clinical performance even in low fetal fraction samples. Importantly, we can help more patients receive reliable results without added complexity for providers.” References Wright et al. Ultrasound Obstet Gynecol. 2015;45(1):48-54. Canick et al. Prenat Diagn. 2013; 33: 667-674. About Natera Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov. View source version on businesswire.com: https://www.businesswire.com/news/home/20260525746777/en/ Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com Original: Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology

Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in OncologyMay 21, 2026 5:05 PM
Business Wire Overall program, including 3 oral presentations, delivers unmatched evidence across the MRD landscape Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place May 29–June 2 in Chicago, IL. Together with its collaborators, Natera will demonstrate unmatched scale in evidence generation with 35 abstracts across molecular residual disease (MRD) testing and other innovations. Presentations will highlight Natera’s Treatment on MRD (TOMR) approach, showing more precise intervention upon molecular recurrence; the broad utility of Signatera as a pan-cancer foundational tool in MRD; the robust clinical performance of Natera’s ultrasensitive phased variant technology; and new real-world data on Signatera in hereditary risk assessment, treatment response monitoring, and longitudinal disease management. “This is the most comprehensive oncology data program Natera has presented to date, reflecting the growing adoption of Signatera and the accelerating momentum behind precision MRD-guided care,” said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology. “Collectively, these studies reinforce Signatera’s broad clinical utility, highlight the continued advancement of our technology platform, and demonstrate the strength and depth of our evidence as we work to make cancer care more actionable and personalized.” Treatment on MRD (TOMR) in Colorectal Cancer (CRC) Multiple analyses from the GALAXY study in CRC demonstrate the value of serial Signatera testing and the potential impact of MRD-guided decision making in the adjuvant setting. In one analysis, patients who were initially Signatera-negative but later converted to Signatera-positive derived a substantial benefit from adjuvant chemotherapy (ACT) (HR 0.3), showing Signatera can identify a subset of patients with early molecular recurrence who could benefit from ACT. Patients with sustained negativity had excellent outcomes regardless of ACT, suggesting potential overtreatment. A separate analysis showed that extending ACT beyond three months provided no added benefit for patients with sustained Signatera-negativity or Signatera clearance, whereas partial molecular responders (decrease in ctDNA) benefitted from continued ACT. Molecular progression (increase in ctDNA) on ACT indicated the need for more effective alternative treatment strategies. Pan-Cancer MRD Natera will present a large, first-of-its-kind, real-world meta-analysis of Signatera across 18 published studies, more than 3,000 patients, and 15 tumor types. The analysis demonstrated that Signatera-positivity was strongly associated with increased risk of recurrence or disease progression at all timepoints included in the analysis. In a pooled analysis, Signatera-positivity in the adjuvant window was associated with significantly increased risk of recurrence or death (HR: 8.15). In the surveillance setting, Signatera-positivity was associated with an even greater recurrence risk (HR: 18.30). Phased Variant Technology Natera’s phased variant technology continues to demonstrate powerful prognostic performance across both solid and hematologic cancers. This technology, which can detect circulating tumor DNA (ctDNA) levels below 1 part per 10 million, reinforces the potential of ultra-sensitive ctDNA detection to guide treatment response monitoring and long-term disease management. One study in early-stage, non-small cell lung cancer (NSCLC), showed that 100% of patients who cleared ctDNA during or after adjuvant therapy did not recur. ctDNA detection also preceded recurrence in 94% of cases. In a separate analysis in relapsed or refractory follicular lymphoma, patients treated with CAR T cell therapy who achieved MRD-negativity experienced substantially improved progression-free survival (PFS), including 36-month PFS rates of 81% compared to 56% in MRD-positive patients. Platform Expansion: RWD and New Digital Tools Natera and its collaborators will present real world data evaluating ctDNA dynamics and clinical outcomes in colorectal cancer, NSCLC, breast cancer, and additional tumor types. Natera will also unveil its Annotation platform at ASCO, a new digital tool that integrates clinical, treatment, and genomic data to present multimodal, longitudinal patient journeys through a unified interface, bringing richer clinical context to Signatera results at the individual and cohort levels. A full list of abstracts is included here. About Natera Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov. View source version on businesswire.com: https://www.businesswire.com/news/home/20260521853793/en/ Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com Original: Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology

EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients EnrolledMay 20, 2026 7:00 AM
Business Wire Milestone follows prestigious oral plenary presentation of EXPAND data at SMFM Annual Meeting Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that the EXPAND clinical trial has enrolled over 2,000 patients, more than doubling enrollment in the last 12 months. EXPAND is a prospective, blinded, multi-site clinical trial designed to study Natera’s Fetal Focus single-gene noninvasive prenatal test (NIPT). The trial was featured in an oral plenary session at the Society for Maternal-Fetal Medicine (SMFM) Annual Meeting in February 2026. The presentation highlighted strong clinical performance in the first milestone readout of EXPAND, as well as the study’s rigorous design, including confirmation of all outcomes against genetic truth. Fetal Focus provides fetal risk assessment for 21 genes associated with serious, early-onset medical conditions. The test is an option for pregnant patients who test positive with Natera’s Horizon™ carrier screen when the father is unavailable for guideline-recommended carrier testing.1 It incorporates Natera’s proprietary ultra-sensitive LinkedSNP™ technology to determine whether a fetus has inherited disease-causing variants from one or both parents. In difficult homozygous cases, where the child inherits the same variant from both parents, Natera’s technology has performed well, identifying 5 out of 5 such cases.2-3 “In developing Fetal Focus, our goal has been to expand the scope of what noninvasive prenatal testing can deliver,” said Sheetal Parmar, SVP of Medical Affairs, Women’s Health at Natera. “With more than 2,000 patients enrolled, EXPAND is helping to set a new standard for clinical evidence in single-gene NIPT, and we remain focused on generating high-quality data to support clinicians and the families they serve.” References ACOG Committee Opinion #690, Mar 2017. Internal data on file. In EXPAND, the study participants and investigators are blinded to the Fetal Focus™ test results. EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). https://clinicaltrials.gov/study/NCT06808880. Accessed May 2026. About Natera Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov. View source version on businesswire.com: https://www.businesswire.com/news/home/20260520113179/en/ Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com Original: EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled

Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)May 15, 2026 12:45 PM
Business Wire Marks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions Solidifies Natera’s Treatment on MRD (TOMR) approach as the new standard of care in MIBC, enabling precision interventions for MRD-positive patients while sparing MRD-negative patients from potentially unnecessary treatment Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq®) immunotherapy in MIBC. This is the first companion diagnostic approval in the field of blood-based MRD. It is a significant milestone in the industry-wide shift toward personalized, MRD-guided cancer care, in which treatment decisions may depend on Signatera™ MRD status, and interventions may be delayed or deferred for patients who remain MRD-negative. Supported by more than 185 peer-reviewed publications and Medicare coverage across multiple cancer types (including Bladder, Breast, Lung, Colorectal, Ovarian, and pan-cancer immunotherapy monitoring), Signatera has become a cornerstone of precision oncology. Signatera CDx has been approved by the FDA for use with adjuvant atezolizumab (Tecentriq®) to identify patients with MIBC who are ctDNA MRD-positive and may benefit from treatment. This follows The New England Journal of Medicine publication in October 2025 of the landmark, global Phase III IMvigor011 trial, sponsored by Genentech. The trial results demonstrated that Signatera MRD-positive patients treated with immunotherapy achieved significant improvements in disease-free survival (DFS) and overall survival (OS), while Signatera MRD-negative patients achieved 97% 2-year OS with no adjuvant therapy at all. “The practice-changing IMvigor011 trial and this approval signal a transformation in cancer care, where MRD is guiding when to treat, whom to treat, and how to treat more precisely,” said Professor Thomas Powles, lead principal investigator of IMvigor011 and Chair of Barts Cancer Centre at St. Bartholomew’s Hospital. “Historically, we relied on imaging to tell us when cancer had returned, but that also meant millions of cancer cells were already present in the body. As we saw with IMvigor011 and in several other trials, Signatera detected tumor DNA at an earlier timepoint and provided us with a significant head start to improve outcomes for patients.” “For bladder cancer patients and families, the period after bladder removal can be filled with uncertainty,” said Meri-Margaret Deoudes, CEO of the Bladder Cancer Advocacy Network. “Approaches like Signatera can help clarify which patients are more likely to experience recurrence, giving clinicians additional important information as they consider next steps. Our priority is ensuring that patients and families have access to tools that support informed decision-making, reduce unnecessary treatment when possible, and help guide timely care when it’s needed.” “This FDA approval is a major milestone for the field of precision oncology and personalized medicine,” said Solomon Moshkevich, president of clinical diagnostics at Natera. “This validates the vision that Natera introduced 10 years ago and solidifies Signatera MRD as the new standard of care in muscle-invasive bladder cancer. With our growing portfolio of TOMR trials and our recent innovations in ultrasensitive genome-based MRD and phased variant technologies, Natera continues to drive forward the science across all cancer types.” There are approximately 30,000 new diagnoses of MIBC each year in the U.S. and 150,000 globally.1-5 Radical cystectomy, with or without neoadjuvant therapy, is associated with long-term disease control in approximately half of patients with muscle-invasive bladder cancer, but it has historically been difficult to identify which patients are likely to recur and to offer them effective, personalized therapy while sparing others from unnecessary treatment.5-6 With IMvigor011, there is now prospective evidence showing that MRD can guide care for patients in this setting and adds to the growing body of evidence on Signatera across the bladder cancer continuum. Notes Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. References https://seer.cancer.gov/statfacts/html/urinb.html Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404-423. doi:10:3322/caac.21631 Global Cancer Observatory. Cancer Today GLOBOCAN 2022 Factsheet – Bladder [Internet; cited 2025 October]. Ghandour R, et al. Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer. Trends Cancer. 2019;5(7):426-39. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–675. doi:10.1200/JCO.2001.19.3.666 Yafi FA, Aprikian AG, Chin JL, et al. Contemporary outcomes of 2,287 patients with bladder cancer treated with radical cystectomy: a Canadian multicentre experience. BJU Int. 2011;108(4):539–545. doi:10.1111/j.1464-410X.2010.09912.x About Natera Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 350 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov. View source version on businesswire.com: https://www.businesswire.com/news/home/20260514529026/en/ Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com Original: Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)

Court orders 30% ongoing royalty for Natera in patent disputeApril 9, 2026 9:52 AM
IH Market News
Natera Inc. (NASDAQ:NTRA) said a federal court in Delaware has ruled that the company is entitled to a 30% ongoing royalty on certain revenues tied to infringing minimal residual disease-related product sales in its patent case against ArcherDx and Invitae.The ruling, issued on April 6, 2026, follows an earlier injunction granted on November 21, 2023. The royalty will apply to revenue generated after the injunction from products that fall under specific exceptions to that order. Previously, a jury had set an effective royalty rate of 20.5% on revenue earned before the injunction, which remains unchanged.The court also reaffirmed the validity of the three minimal residual disease patents at the center of the case and upheld damages associated with Invitae’s products in this segment. In addition, the jury’s findings on patent validity and direct infringement related to non-minimal residual disease products were left in place.Natera is a precision medicine company specializing in cell-free DNA testing across oncology, women’s health and organ health. The firm holds more than 650 issued or pending patents, including several covering minimal residual disease diagnostics.Natera stock price

Original: Court orders 30% ongoing royalty for Natera in patent dispute

Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related PatentsApril 9, 2026 6:00 AM
Business Wire
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update on a recent decision issued by the United States District Court in the District of Delaware regarding Natera’s litigation with ArcherDx and Invitae.


In a decision issued on April 6, 2026, the Court ordered an ongoing royalty to Natera of 30% on post-injunction revenues from infringing MRD-related product sales that fall within the exceptions to the injunction, which was issued by the Court on November 21, 2023. The jury had awarded an effective royalty of 20.5% on pre-injunction revenues, which remains unchanged. With respect to the non-MRD products, the jury’s verdict of patent validity and direct infringement also remains intact.


The Company stated:


“Natera is pleased that the Court upheld the validity of all three asserted MRD patents and preserved damages related to Invitae’s MRD-related products. The decision confirms a 30% ongoing royalty on post-injunction revenues and reinforces the strength of Natera’s innovation in this space.”


Natera has over 650 issued or pending patents, including a strong portfolio of MRD patents.


About Natera


Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.


Forward-Looking Statements


All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to developments in matters under dispute or litigation, or the scope of protection we establish and maintain for, and developments or disputes concerning, our intellectual property or other proprietary rights. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409795411/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com


Original: Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology PlatformApril 7, 2026 6:00 AM
Business Wire
Data from >75,000 patients underscore advances in AI-driven virtual genomics, Signatera™-guided treatment monitoring, and continued expansion of MRD and other capabilities


Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts, including two oral presentations, featuring data generated using its technologies will be presented at the 2026 American Association for Cancer Research® (AACR) Annual Meeting 2026, taking place April 17–22 in San Diego, CA.


These presentations, developed in collaboration with leading academic and clinical partners, span multiple tumor types and applications, including artificial intelligence, digital pathology, molecular residual disease (MRD) and real-world evidence (RWE).


“These presentations reflect both the scale of our platform and the pace of innovation we’re driving across oncology,” said Alexey Aleshin, M.D., corporate chief medical officer and general manager, oncology and early cancer detection at Natera. “From AI-enabled genomic insights to real-world evidence supporting ctDNA-guided treatment decisions, this body of work demonstrates how we are continuing to innovate within and beyond MRD to deliver more precise, data-driven approaches across cancer care.”


Key highlights


Artificial Intelligence



Natera’s oral presentation, A large-scale, multi-target deep learning model for virtual genomic profiling in colorectal cancer, describes a digital pathology deep learning model trained on molecular and histopathology data from more than 45,000 colorectal cancer patients in a first-of-its-kind analysis. The model predicts risk of recurrence, hundreds of genomic alterations and key guideline biomarkers directly from routine H&E images, with an industry-leading area under the receiver operating curve (AUROC) of 0.98 for MSI-status and 0.93 for BRAF V600E status. This highlights the potential to transform routine pathology slides into a scalable, AI-enabled genomic profiling platform, expanding access to high-value molecular data, reducing tissue constraints and accelerating time to treatment decisions.



An additional poster in breast cancer, A machine learning approach to classify breast cancer receptor subtype using genomic features, analyzed data from nearly 20,000 patients. The study concluded that a machine learning model using tumor DNA can accurately classify breast cancer into its major subtypes, including high precision of 93.5% and recall of 91.1% for identifying HR+/HER2- disease.



ctDNA Decision-Making



A second oral presentation, Circulating tumor DNA (ctDNA) clearance dynamics in microsatellite instability-high metastatic (MSI-H) colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI), includes a real-world analysis of 465 patients with MSI-H metastatic CRC treated with ICI. The data shows that ~40% of patients had early ctDNA clearance on ICI. Signatera negativity at the first post-ICI timepoint was predictive of overall survival (OS), with 3-year OS of 96%. Moreover, MRD dynamics were strongly associated with improved OS with 65% of Signatera-positive patients achieving clearance anytime on or post-ICI.



Platform Expansion



A poster on Natera’s methylation-based, tissue-free MRD platform entitled, Quantification of circulating tumor DNA (ctDNA) in patients using cancer-specific, methylation-based, tissue-free tests for the detection of molecular residual disease (MRD), shows that quantitative ctDNA levels strongly correlate with Signatera quantitative levels across colorectal, breast, lung and bladder cancers. LatitudeTM, Natera’s tissue-free MRD assay, launched in CRC in 2025 and is expected to launch commercially in additional histologies with quantitative features later this year.



A poster in early cancer detection, Performance of a blood-based screening test for the early detection of advanced precancerous lesions, summarizes previously announced PROCEED trial data that showed strong performance of Natera’s blood-based screening assay for detecting advanced precancerous lesions. The study demonstrated sensitivity of 22.5% (CI: 15.4%-32.4%) and specificity of 91.5% (CI: 88.2%-93.9%)?? and encompassed all histologic subtypes, including serrated polyps.



A full list of abstracts is included here.


About Natera


Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.


Forward-Looking Statements


All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.


This release is not affiliated with or endorsed by AACR.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260407837545/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com


Original: 20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform

Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal CancersMarch 16, 2026 6:00 AM
Business Wire
New findings show that Signatera status can help identify high-risk patients and inform non-operative management and surveillance strategies


Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced two peer-reviewed publications highlighting the clinical utility of Signatera, its personalized, tumor-informed circulating tumor DNA (ctDNA) assay, in anal squamous cell carcinoma (ASCC) and locally advanced rectal cancer (LARC).


ASCC: publication in Nature Communications


A recently published study evaluated 84 patients with ASCC to assess whether serial Signatera testing may offer a dynamic, treatment-responsive biomarker to further stratify recurrence risk and inform surveillance and treatment. Key findings include:



Signatera-status was strongly correlated with clinical outcomes. Patients who were Signatera-negative at baseline or cleared ctDNA during chemoradiotherapy (CRT) had favorable outcomes, including 100% one-year overall survival and progression-free survival, and 0% one-year local regional failure. Patients who remained ctDNA-positive after CRT had poorer outcomes (63% OS, 44% PFS, 39% locoregional failure at one year).



In 100% of recurrent cases, Signatera-positivity preceded clinical and/or radiographic recurrence highlighting ctDNA’s potential as an early indicator of relapse.



LARC: publication in Cancers


Another recent study evaluated 220 patients with LARC treated with neoadjuvant therapy (NAT) followed by non-operative management (NOM) (n=72) or surgery (n=148). The study examined how Signatera status after NAT may inform patient selection for organ-preserving NOM versus surgery and guide intensified surveillance strategies. Key findings include:



Signatera identified post-NAT patients at high risk of relapse requiring surgical intervention. Signatera-positive NOM patients were at 4.6x higher risk of regrowth requiring surgery (HR 4.62; p=0.003), even among those with a complete or near-complete clinical response.



Post-operative Signatera negativity was associated with excellent clinical outcomes. Signatera-negative patients (HR:15, p=0.001) experienced a relapse rate of 11.5% compared to 88.0% among Signatera-positive patients (p

Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder PreservationFebruary 27, 2026 10:05 AM
Business Wire
11 scientific abstracts, including 4 oral presentations and a concurrent publication in Nature Medicine, underscore how Signatera MRD can improve quality of life for patients with genitourinary cancers


Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026.


Across four oral presentations in muscle-invasive bladder cancer (MIBC), these data reinforce Signatera’s role in identifying patients who benefit from adjuvant immunotherapy, supporting response-adaptive bladder preservation strategies, and refining molecular residual disease (MRD) detection with plasma circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA).


Bladder Preservation: INDIBLADE and RETAIN


The INDIBLADE and RETAIN multicenter phase 2 trials demonstrate Signatera’s consistent performance in treatment response monitoring across diverse neoadjuvant regimens in MIBC, with 73-77% of patients demonstrating clearance of ctDNA following therapy and Signatera-negativity showing strong associations with positive outcomes, even with the bladder preserved.


INDIBLADE, the findings of which will be published today in Nature Medicine, investigated induction with combination immune checkpoint inhibitors (ICI) followed by chemoradiotherapy as a bladder-sparing strategy in stage II/III MIBC patients. The results show that Signatera status post-ICI was associated with bladder-intact event-free survival (BI-EFS). Specifically, Signatera-negativity at baseline and post-neoadjuvant therapy was linked to an 88.6% and 91% estimated two-year BI-EFS, respectively.


RETAIN evaluated a clinical response-adapted approach to identify patients for potential bladder-preservation following neoadjuvant therapy. The findings showed that post-treatment ctDNA clearance or negativity was associated with improved metastasis-free survival (MFS), and that Signatera-negative patients with no clinical or radiographic evidence of disease managed with active surveillance achieved MFS comparable to Signatera-negative patients undergoing cystectomy. In contrast, persistent Signatera-positivity was associated with poor outcomes.


Perioperative Care: NIAGARA


This phase 3 randomized perioperative study includes the first-ever presentation of utDNA data with clinical correlation. The combination of utDNA and ctDNA status post-neoadjuvant therapy and pre-cystectomy identified the group with the highest 24-month EFS. utDNA-positivity pre-cystectomy was more strongly associated with residual non-invasive disease vs ctDNA-positivity was more strongly associated with residual invasive disease. These data suggest that the combined assessment of utDNA and ctDNA can provide complementary risk stratification benchmarked against pathologic staging, enabling comprehensive identification of residual disease.


“As treatment options expand in perioperative and bladder preservation settings, we need tools that help us determine who truly requires additional therapy and who may safely avoid it,” said Michiel van der Heijden, M.D., Ph.D., Netherlands Cancer Institute, principal investigator of INDIBLADE and presenting author of the NIAGARA study. “The data presented at ASCO GU demonstrate that MRD assessment with Signatera has strong correlations with outcomes and the potential to inform these critical treatment decisions.”


“Following our milestone PMA submission to the FDA based on IMvigor011, these compelling data presentations reflect our commitment to transforming care across the spectrum of genitourinary malignancies,” said Minetta Liu, M.D., chief medical officer of oncology and early cancer detection at Natera. “The new data suggests a particularly important opportunity for Signatera to optimize clinical decisions around bladder preservation, a major opening to improve patient quality of life.”


The full list of presentations at ASCO GU includes:


February 27, 8:10 AM PT | Abstract #633 (Oral Presentation)

Presenter: Joaquim Bellmunt, M.D.

Circulating tumor (ct)DNA-guided adjuvant atezolizumab (atezo) in muscle-invasive bladder cancer (MIBC): Exploratory analysis of ctDNA dynamics in the IMvigor011 trial


February 27, 8:10 AM PT | Abstract #632 (Oral Presentation)

Presenter: Pooja Ghatalia, M.D.

Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): Integrated analysis of the RETAIN trials


February 27, 11:30 AM PT | Abstract #797

Presenter: Can Aydogdu, M.D.

Integrating genomic profiling and circulating tumor DNA monitoring to optimize surveillance strategies in muscle-invasive bladder cancer


February 27, 11:30 AM PT | Abstract #831

Presenter: Can Aydogdu, M.D.

Association of ctDNA status with upstaging, pathologic outcomes, and genomic alterations in high-risk NMIBC


February 27, 2:30 PM PT | Abstract #637 (Oral Presentation)

Presenter: Jan-Jaap J. Mellema, M.D.

Induction ipilimumab plus nivolumab followed by consolidating chemoradiotherapy as bladder-sparing treatment in stage II/III urothelial carcinoma of the bladder: The phase 2 INDIBLADE trial


February 27, 4:00 PM PT | Abstract #636 (Oral Presentation)

Presenter: Michiel van der Heijden, M.D., Ph.D.

Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA


February 28, 7:00 AM PT | Abstract #532

Presenter: Shuchi Gulati, M.D., M.Sc.

Association of pre-operative circulating tumor DNA (ctDNA) status with clinicopathologic characteristics in patients (pts) with localized renal cell carcinoma (RCC)


February 28, 7:00 AM PT | Abstract #620

Presenter: Dalia Kaakour, M.D., MPH

Use of circulating tumor DNA (ctDNA) in the detection of residual disease and recurrence for patients with testicular cancer


February 27, 11:30 AM PT | Abstract #860

Presenter: Lingbin Meng, M.D., Ph.D.

Use of circulating tumor DNA (ctDNA) in the detection of residual disease and recurrence for patients with testicular cancer


February 27, 11:30 AM PT | Abstract #800

Presenter: Tanya Jindal, BS, BA

Predictive value of early circulating tumor DNA (ctDNA) response in advanced urothelial carcinoma (aUC) treated with enfortumab vedotin plus pembrolizumab (EVP).


February 28, 7:00 AM PT | Abstract #541

Presenter: David F. McDermott, M.D.

Circulating tumor DNA (ctDNA) analysis in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC) treated with first-line pembrolizumab (pembro) monotherapy from the phase 2 KEYNOTE-427 study.


About Natera


Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 350 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.


Forward-Looking Statements


All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260227178662/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com


Original: Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

Natera Reports Fourth Quarter and Full Year 2025 Financial ResultsFebruary 26, 2026 4:05 PM
Business Wire
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2025.


Recent Financial Highlights



Generated total revenues of $665.5 million in the fourth quarter of 2025, compared to $476.1 million in the fourth quarter of 2024, an increase of 39.8%. Product revenues grew 39.8% over the same period.



Generated a gross margin1 of 66.9% in the fourth quarter of 2025, compared to a gross margin1 of 62.9% in the fourth quarter of 2024.



Generated total revenues of $2,306.1 million in the full year 2025, compared to $1,696.9 million in the full year 2024, an increase of 35.9%. Product revenues grew 36.2% over the same period.



Generated a gross margin1 of 64.7% in the full year of 2025, compared to a gross margin1 of 60.3% in the full year of 2024.



Processed approximately 923,600 tests in the fourth quarter of 2025, compared to approximately 792,800 tests in the fourth quarter of 2024, an increase of 16.5%.



Processed approximately 3,525,500 tests in the full year 2025, compared to approximately 3,064,600 tests in the full year 2024, an increase of 15.0%.



Processed approximately 233,300 oncology tests in the fourth quarter of 2025, compared to approximately 150,800 in the fourth quarter of 2024, an increase of 54.7%.



Processed approximately 800,800 oncology tests in the full year 2025, compared to approximately 528,200 in the full year 2024, an increase of 51.6%.



Achieved positive cash inflow of approximately $107.6 million2 in the full year 2025.



“We delivered an outstanding finish to 2025 with record test volumes, strong revenue that exceeded our January pre-announcement, and gross margins well ahead of our expectations even as we continued to invest significantly throughout the year,” said Steve Chapman, chief executive officer of Natera. “With solid momentum already in 2026, we remain focused on our mission to transform the management of disease worldwide by expanding access to our testing and advancing the data that supports better patient care.”


Fourth Quarter and Year Ended December 31, 2025 Financial Results


Total revenues were $665.5 million in the fourth quarter of 2025 compared to $476.1 million in the fourth quarter of 2024, an increase of 39.8%. The increase in total revenues was driven primarily by a 39.8% increase in product revenues, which were $661.2 million in the fourth quarter of 2025 compared to $472.9 million in the fourth quarter of 2024. The increase in product revenues was driven by an increase in volume and average selling price improvements.


Natera processed approximately 923,600 tests in the fourth quarter of 2025, including approximately 909,000 tests accessioned in its laboratory, compared to approximately 792,800 tests processed, including approximately 778,400 tests accessioned in its laboratory, in the fourth quarter of 2024.


In the fourth quarter of 2025, Natera recognized revenue on approximately 892,400 tests for which results were reported to customers in the period (tests reported), including approximately 878,000 tests reported from its laboratory, compared to approximately 771,700 tests reported, including approximately 758,200 tests reported from its laboratory, in the fourth quarter of 2024, an increase of 15.6% from the prior period.


Total revenues were $2,306.1 million in the full year 2025 compared to $1,696.9 million in the full year 2024, an increase of 35.9%. The increase in total revenues was driven primarily by a 36.2% increase in product revenues, which were $2,295.8 million in the full year 2025 compared to $1,685.1 million in the full year 2024. The increase in product revenues was driven by an increase in volume and average selling price improvements.


Natera processed approximately 3,525,500 tests in the full year 2025, including approximately 3,468,700 tests accessioned in its laboratory, compared to approximately 3,064,600 tests processed, including approximately 3,001,900 tests accessioned in its laboratory, in the full year 2024.


In the full year 2025, Natera recognized revenue on approximately 3,342,500 tests for which results were reported to customers in the period (tests reported), including approximately 3,288,600 tests reported from its laboratory, compared to approximately 2,926,400 tests reported, including approximately 2,867,400 tests reported from its laboratory, in the full year 2024, an increase of 14.2% from the prior period.


Gross profit2 for the three months ended December 31, 2025 and 2024 was $445.2 million and $299.6 million, respectively, representing a gross margin1 of 66.9% and 62.9%, respectively. Gross profit1 for the year ended December 31, 2025 and 2024 was $1,493.2 million and $1,023.2 million, respectively, representing a gross margin1 of 64.7% and 60.3%, respectively. Natera had higher gross margin1 in the fourth quarter of 2025 and for the full year 2025 primarily as a result of higher revenues and continued progress in reducing cost of revenues associated with tests processed. Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the fourth quarter of 2025 was $466.5 million, compared to $364.4 million in the same period of the prior year, an increase of 28.0%. Total operating expense for the full year 2025 were $1,801.4 million, compared to $1,245.5 million in the same period of the prior year, an increase of 44.6%. The increases in both periods were primarily driven by headcount growth to support new product offerings as well as increases in consulting and legal expenses. Amortization of acquired intangible assets for the fourth quarter and full year of 2025 was $1.7 million. No such amortization occurred in the fourth quarter or full year of 2024.


Loss from operations for the fourth quarter of 2025 was $22.8 million compared to $64.7 million for the same period of the prior year. Loss from operations for full year 2025 was $309.9 million compared to $222.3 million for the same period of the prior year.


Natera’s net loss for the full year 2025 was $208.2 million, or ($1.52) per diluted share, compared to a net loss of $190.4 million, or ($1.53) per diluted share, in 2024. Weighted average shares outstanding were 136.7 million in the full year 2025 compared to 124.7 million for the same period in the prior year.


At December 31, 2025, Natera held approximately $1,076.1 million in cash, cash equivalents, short-term investments and restricted cash, compared to $968.3 million as of December 31, 2024. As of December 31, 2025, Natera had a total outstanding debt balance of $80.3 million including accrued interest under its line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps.


Financial Outlook


Natera anticipates 2026 total revenue of $2.62 billion to $2.70 billion; 2026 gross margin1 to be approximately 63% to 65%; selling, general and administrative costs to be approximately $1.125 billion to $1.225 billion; research and development costs to be $750 million to $850 million; and net cash inflow to be positive3.




Test Volume Summary








Unit






Q4 2025





 

Q4 2024





 

FY 2025





 

FY 2024





 

Definition








Tests processed






923,600





 

792,800





 

3,525,500





 

3,064,600





 

Tests accessioned in our laboratory plus units processed outside of our laboratory








Tests accessioned






909,000





 

778,400





 

3,468,700





 

3,001,900





 

Test accessioned in our laboratory








Tests reported






892,400





 

771,700





 

3,342,500





 

2,926,400





 

Total tests reported








Tests reported in our laboratory






878,000





 

758,200





 

3,288,600





 

2,867,400





 

Total tests reported in our laboratory less units reported outside of our laboratory







About Natera


Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 350 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.




Conference Call Information








 






 








Event:






Natera’s Fourth Quarter and Full Year 2025 Financial Results Conference Call








Date:






Thursday, February 26, 2026








Time:






1:30 p.m. PT (4:30 p.m. ET)








Live Dial-In:






1-888-770-7321 (Domestic)

1-929-201-7107 (International)








Conference ID:






7684785








Webcast Link:






https://events.q4inc.com/attendee/730547572







Forward-Looking Statements


This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our market opportunity, anticipated products and launch schedules, reimbursement coverage and product costs, commercial and strategic partnerships and acquisitions, user experience, clinical trials and studies, and our strategies, goals and general business and market conditions, are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera’s current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved.


These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to further increase the use and adoption of our products through our direct sales efforts or through our laboratory partners; we have incurred net losses since our inception and we anticipate that we will continue to incur net losses for the foreseeable future; our quarterly results may fluctuate from period to period; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our financial resources; our products may not perform as expected; the results of our clinical studies may not support the use and reimbursement of our tests, particularly for microdeletions screening, and may not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA-certified laboratories becomes inoperable, we will be unable to perform our tests and our business may be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and reimbursement for our tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors; we could incur substantial costs and delays complying with governmental regulations; litigation and other regulatory or governmental proceedings related to our intellectual property or the commercialization of our tests, are costly, time-consuming, could result in our obligation to pay material judgments or incur material settlement costs, and could limit our ability to commercialize our tests; and any inability to effectively protect our proprietary technology could harm our competitive position or our brand.


We discuss these and other risks and uncertainties in greater detail in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our periodic reports on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. These documents are available on our website at www.natera.com under the Investor Relations section and on the SEC’s website at www.sec.gov.


We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, you should not place undue reliance on our forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.


References:



Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. Gross margin is calculated as gross profit divided by GAAP total revenues.



Positive cash inflow for the year ended December 31, 2025, is derived from the GAAP Statement of Cash Flows as follows: net cash provided by operating activities of $215.3 million, net cash provided by financing activities of $47.5 million, offset by net cash used in investing activities for purchases of property and equipment, cash paid for acquisition of intangible assets, and cash paid for business combination of $155.2 million.



Non-GAAP cash (outflow) inflow is calculated as the sum of GAAP net cash provided by (used in) operating activities, GAAP net cash provided by (used in) financing activities, and GAAP net cash provided by (used in) investing activities for purchases of property and equipment, investment in related party, cash paid for acquisition of intangible assets, and cash paid for business combination. Management uses non-GAAP cash flow as an indicator of the Company’s operational cash generating capabilities.




 



Natera, Inc.




Consolidated Balance Sheets




(Unaudited)




(in thousands, except shares)












 



 






 






December 31,






 






December 31,






 








 






 






2025






 






2024






 








 






 






 






 






(1)






 








Assets






 






 






 






 






 






 






 








Current assets:






 






 






 






 






 






 






 








Cash, cash equivalents and restricted cash






 






$






1,076,140






 






 






$






945,587






 






 








Short-term investments






 






 






—






 






 






 






22,689






 






 








Accounts receivable, net of allowance of $8,018 in 2025 and $7,259 in 2024






 






 






296,528






 






 






 






314,165






 






 








Inventory






 






 






68,443






 






 






 






44,744






 






 








Prepaid expenses and other current assets






 






 






55,828






 






 






 






48,635






 






 








Total current assets






 






 






1,496,939






 






 






 






1,375,820






 






 








Property and equipment, net






 






 






241,184






 






 






 






162,046






 






 








Operating lease right-of-use assets






 






 






108,541






 






 






 






86,149






 






 








Goodwill






 






 






141,070






 






 






 






—






 






 








Intangible assets






 






 






373,713






 






 






 






10,933






 






 








Other assets






 






 






36,897






 






 






 






25,787






 






 








Total assets






 






$






2,398,344






 






 






$






1,660,735






 






 








 






 






 






 






 






 






 






 








Liabilities and Stockholders’ Equity






 






 






 






 






 






 






 








Current liabilities:






 






 






 






 






 






 






 








Accounts payable






 






$






33,156






 






 






$






34,922






 






 








Accrued compensation






 






 






92,603






 






 






 






62,114






 






 








Contingent consideration payable, current portion






 






 






21,580






 






 






 






—






 






 








Deferred revenue, current portion






 






 






24,907






 






 






 






19,754






 






 








Short-term debt financing






 






 






80,323






 






 






 






80,362






 






 








Other accrued liabilities






 






 






188,659






 






 






 






146,893






 






 








Total current liabilities






 






 






441,228






 






 






 






344,045






 






 








Contingent consideration payable, long-term portion






 






 






96,780






 






 






 






—






 






 








Deferred tax liability, long-term portion






 






 






701






 






 






 






—






 






 








Operating lease liabilities, long-term portion






 






 






118,473






 






 






 






96,588






 






 








Deferred revenue, long-term portion






 






 






17,062






 






 






 






16,838






 






 








Other liabilities






 






 






11,687






 






 






 






7,844






 






 








Total liabilities






 






 






685,931






 






 






 






465,315






 






 








Commitments and contingencies






 






 






 






 






 






 






 








Stockholders’ equity:






 






 






 






 






 






 






 








Common stock (2)






 






 






14






 






 






 






12






 






 








Additional paid in capital






 






 






4,488,679






 






 






 






3,763,614






 






 








Accumulated deficit






 






 






(2,776,022






)






 






 






(2,567,862






)






 








Accumulated other comprehensive loss






 






 






(258






)






 






 






(344






)






 








Total stockholders’ equity






 






 






1,712,413






 






 






 






1,195,420






 






 








Total liabilities and stockholders’ equity






 






$






2,398,344






 






 






$






1,660,735






 






 









(1)






The consolidated balance sheet at December 31, 2024 has been derived from the audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.








(2)






As of December 31, 2025 and December 31, 2024, there were approximately 139,693,000 and 132,646,000 shares of common stock, respectively, issued and outstanding.









 









Natera, Inc.




Consolidated Statements of Operations and Comprehensive Loss




(Unaudited)




(in thousands, except per share data)










 



 






 






Year ended December 31,






 








 






 






2025






 






 






2024






 






 






2023






 






 








 






 






 






 






 






 






 






 






 








Revenues






 






 






 






 






 






 






 






 






 






 








Product revenues






 






$






2,295,820






 






 






$






1,685,074






 






 






$






1,068,522






 






 








Licensing and other revenues






 






 






10,293






 






 






 






11,837






 






 






 






14,049






 






 








Total revenues






 






 






2,306,113






 






 






 






1,696,911






 






 






 






1,082,571






 






 








Cost and expenses






 






 






 






 






 






 






 






 






 






 








Cost of product revenues






 






 






810,627






 






 






 






672,304






 






 






 






588,564






 






 








Cost of licensing and other revenues






 






 






2,306






 






 






 






1,449






 






 






 






1,267






 






 








Research and development






 






 






624,110






 






 






 






404,138






 






 






 






320,678






 






 








Selling, general and administrative






 






 






1,177,261






 






 






 






841,314






 






 






 






618,307






 






 








Amortization of acquired intangible assets






 






 






1,720






 






 






 






—






 






 






 






—






 






 








Total cost and expenses






 






 






2,616,024






 






 






 






1,919,205






 






 






 






1,528,816






 






 








Loss from operations






 






 






(309,911






)






 






 






(222,294






)






 






 






(446,245






)






 








Interest expense






 






 






(4,069






)






 






 






(10,685






)






 






 






(12,638






)






 








Interest and other income, net






 






 






45,891






 






 






 






43,248






 






 






 






24,353






 






 








Loss before income taxes






 






 






(268,089






)






 






 






(189,731






)






 






 






(434,530






)






 








Income tax benefit (expense)






 






 






59,929






 






 






 






(695






)






 






 






(271






)






 








Net loss






 






$






(208,160






)






 






$






(190,426






)






 






$






(434,801






)






 








Unrealized gain on available-for-sale securities and foreign currency translation adjustment






 






 






86






 






 






 






2,741






 






 






 






13,277






 






 








Comprehensive loss






 






$






(208,074






)






 






$






(187,685






)






 






$






(421,524






)






 








 






 






 






 






 






 






 






 






 






 






 








Net loss per share:






 






 






 






 






 






 






 






 






 






 








Basic and diluted






 






$






(1.52






)






 






$






(1.53






)






 






$






(3.78






)






 








 






 






 






 






 






 






 






 






 






 






 








Weighted-average number of shares used in computing basic and diluted net loss per share:






 






 






 






 






 






 






 






 






 






 








Basic and diluted






 






 






136,721






 






 






 






124,718






 






 






 






114,997






 






 







 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260226942327/en/
Investor Relations

Mike Brophy, CFO, Natera, Inc., 510-826-2350


Media

Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com


Original: Natera Reports Fourth Quarter and Full Year 2025 Financial Results

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy OutcomesFebruary 6, 2026 6:00 AM
Business Wire
Large prospective study to evaluate a non-invasive prenatal screening test


Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of EDEN, a large, multi-center prospective study designed to evaluate the company’s non-invasive prenatal screening test for early risk assessment of preeclampsia and other serious pregnancy complications.


Preeclampsia affects approximately 5-8% of pregnancies and remains a leading cause of maternal and neonatal morbidity.1 While clinical guidelines recommend low-dose aspirin for patients with established risk factors for preeclampsia2, current risk assessment relies primarily on clinical characteristics and does not provide individualized estimates of risk or response to preventive strategies.3 More broadly, adverse pregnancy outcomes affect an estimated 20% of pregnancies in the United States and are associated with substantial maternal and fetal morbidity and mortality.4


EDEN is designed as a definitive prospective study of Natera’s integrated prenatal risk assessment test, which combines cell-free DNA (cfDNA), additional analytes and clinical data. The study plans to enroll up to 7,500 pregnant participants in the United States between 9 and 15 weeks’ gestation to evaluate risk for preeclampsia, including earlier-onset and more severe disease, along with additional adverse pregnancy outcomes.


Natera’s new test builds on previously published research demonstrating associations between cfDNA characteristics and adverse pregnancy outcomes. These studies showed that cfDNA-derived markers, when combined with patient characteristics, can identify risk for preeclampsia with performance comparable to approaches that rely on specialized imaging or additional biomarkers, and that nonreportable cfDNA results are associated with increased risk of pregnancy complications.5,6


“For more than a decade, Natera has advanced pregnancy care through highly sensitive, non-invasive testing,” said Sheetal Parmar, senior vice president of medical affairs at Natera. “With EDEN, we are evaluating a next-generation test designed to identify pregnancies at increased risk for preeclampsia and other serious complications earlier and with greater precision, using data that are already part of routine prenatal care.”


References



Johns Hopkins Medicine. Preeclampsia: https://www.hopkinsmedicine.org/health/conditions-and-diseases/preeclampsia. Accessed February 2026.



U.S. Preventive Services Task Force. Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force recommendation statement. JAMA. 2017;317(16):1661–1667. doi:10.1001/jama.2017.3439



O’Gorman N, Wright D, Poon LC, et al. Multicenter screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49(6):756–760. doi:10.1002/uog.17399



Khan F, et al. Adverse pregnancy outcomes, including hypertensive disorders, low birthweight, and preterm birth, now complicate nearly 1 in 5 live births in the United States. Curr Opin Obstet Gynecol. 2023.



Khalil A, Bellesia G, Norton ME, et al. The role of cell-free DNA biomarkers and patient data in the early prediction of preeclampsia: an artificial intelligence model. Am J Obstet Gynecol. 2024;231(5):554.e1-554.e18. doi:10.1016/j.ajog.2024.02.299



Norton ME, MacPherson C, Demko Z, et al. Obstetrical, perinatal, and genetic outcomes associated with nonreportable prenatal cell-free DNA screening results. Am J Obstet Gynecol. 2023;229(3):300.e1-300.e9. doi:10.1016/j.ajog.2023.03.026



About Natera


Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 350 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.


Forward-Looking Statements


All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260206350770/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com


Original: Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

Natera Submits Signatera™ CDx PMA to FDAFebruary 2, 2026 6:00 AM
Business Wire
Application backed by landmark phase 3 data validating MRD-guided treatment in bladder cancer


Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for Signatera™ CDx for detection of molecular residual disease (MRD) in patients with muscle-invasive bladder cancer (MIBC) who may benefit from treatment with atezolizumab (Tecentriq®).


This submission is supported by data from the randomized, double-blind, phase 3 IMvigor011 clinical trial, which met its primary endpoint and demonstrated the benefits of Signatera-guided therapy in MIBC. In the study, Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free survival and overall survival, compared with placebo. The trial also showed that Signatera-negative patients had a low risk of recurrence without adjuvant immunotherapy. Results were featured in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress on October 20, 2025, with a concurrent publication in The New England Journal of Medicine.


Bladder cancer is the sixth most common cancer in the United States1 and MIBC represents 20-25% of the newly diagnosed cases.2 Radical cystectomy (with or without neoadjuvant therapy) is curative for approximately half of these patients, but until now it has been very challenging to identify which patients are likely to recur and to offer them effective, personalized therapy while sparing the others from unnecessary treatment.3,4 The IMvigor011 trial, sponsored by Genentech, a member of the Roche Group, was designed to address that challenge.


“Submitting this PMA represents an important step toward making MRD-guided treatment a reality for patients with muscle-invasive bladder cancer,” said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer at Natera. “If approved, we believe Signatera CDx has the potential to be the first companion diagnostic MRD test that helps guide treatment decisions and improve outcomes for patients.”


References



National Comprehensive Cancer Network, Bladder Cancer. NCCN Clinical practice guidelines in oncology (NCCN Guidelines). Version 4.2021.



Gakis G. Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives. Eur. Urol. Focus. 2020;6(4):632-638.



Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–675. doi:10.1200/JCO.2001.19.3.666



Yafi FA, Aprikian AG, Chin JL, et al. Contemporary outcomes of 2,287 patients with bladder cancer treated with radical cystectomy: a Canadian multicentre experience. BJU Int. 2011;108(4):539–545. doi:10.1111/j.1464-410X.2010.09912.x



Notes


Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.


About Natera


Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 350 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.


Forward-Looking Statements


All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260129560151/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com


Original: Natera Submits Signatera™ CDx PMA to FDA

now biggest pstn at Duquesne

NTRA new 52 week high

NTRA new 52=week high

NTRA new 52 week high

Pioneers in individualized genetic testing

Cell-free DNA (cfDNA) can be found in everyone. Not only do our own cells release it, so do fetal, tumor, and donor organ cells. Using a simple blood draw, our technology precisely detects each of these types of cell-free DNA, uniquely for each individual, to help proactively inform their treatment.
With more than 15 years of experience focused in this field, our technology has been used to perform more cell-free DNA tests than any other.

NTRA new 52 week high

NTRA new 52 week high